Cobas taqman assay hiv 1 test version 2

Clinical and laboratory assessments were performed at baseline and at 12 weeks, 24 weeks, 48 weeks, 96 weeks, and 144 weeks of treatment. Absolute CD4+ T lymphocyte (CD3 + CD4 + CD8−) count and CD8+ T lymphocyte (CD3 + CD4 − CD8+) count were measured using a BD CantoII flow cytometer with CD3/CD4/CD8 trichrome fluorescence reagent from BD according to the instructions. BD Multitest™ CD3/CD8/CD45/CD4 IMK Kit used in this study contains FITC-labeled CD3, clone SK7; PE-labeled CD8, clone SK1; PerCP-labeled CD45, clone 2D1 (HLe-1); and APC-labeled CD4, clone SK3. Plasma HIV-1 RNA load was quantified using the Roche COBAS-TaqMan Assay (HIV-1 Test, version 2.0, Indianapolis, IN, United States), and the detection limit was 20 copies/mL. Long-term virological response was defined as HIV-1 RNA <20 copies/mL at week 144 of treatment. Subgenotypes of the HIV-1 virus were tested with the standard strains selected from the Los Alamos HIV database using Bioedit and MEGA5 software, and mutation sites were identified using the Stanford HIV-resistant database (Supplementary Table S1), which has been described elsewhere (7 (link)).

Plasma HIV-1 RNA load was detected using the Roche COBAS-TaqMan Assay (HIV-1 Test, version 2.0, Indianapolis, IN, United states). The target fragment for the subgenotyping includes 99 amino acid coding codons from the protease (PR) region, and resistance analysis consists of approximately 300 amino acid coding codons from the reverse transcriptase region (primer sequences listed in Supplementary Table S1). The subgenotype of HIV-1 was tested using Bioedit and MEGA5 software with the standard strains selected from the Los Alamos HIV database, and mutation sites were identified using the Stanford HIV-resistant database (Rhee et al., 2017 (link); Zhang et al., 2017 (link)).